Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Tidewater Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Tidewater Inc trades at $83.01 (market cap $4.33B). The key difference: Tidewater Inc is far larger — about 4.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Tidewater Inc is more actively traded (553,078 versus 4,325,710). Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Tidewater Inc for 27 Days on average.
| MRVI | TDW | |
|---|---|---|
Market Cap | $972.90M | $4.33B |
Volume | 4,325,710 | 553,078 |
Sector | Health | Energy |
52-Week High | $9.00 | $100.61 |
52-Week Low | $2.83 | $47.29 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $1.08B | $4.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Tidewater (TDW) trades at $86.97, up 0.6% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $105.50. The company reported strong 2025 results with $1.35B revenue and $334.66M net income, though recent quarterly earnings have missed expectations. Positive developments include the completion of the Wilson Sons Ultratug acquisition in August 2026 and a significant $503.2M investment from BlackRock.
The stock offers potential upside to the price target, driven by operational strength and strategic acquisitions. Key risks include earnings volatility, competitive pressures in the energy sector, and exposure to geopolitical tensions affecting day rates. Investor sentiment is mixed, with 30.77% of analysts rating it a buy amid recent insider selling and institutional accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
